The Medicines Company (MDCO) 23.34 $MDCO
ORBACTIV(TM) (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases
Business Wire - Thu Oct 09, 3:53PM CDT
The Medicines Company (NASDAQ:MDCO) today announced the publication of the results from the SOLO II Phase 3 clinical trial of ORBACTIV (oritavancin) for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens.
MDCO: 23.34 (+0.69)
The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014
Business Wire - Wed Oct 08, 6:20PM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, October 22 at 8:30 a.m. Eastern Time to discuss third quarter financial results, guidance and operational developments.
MDCO: 23.34 (+0.69)
RSI Alert: Medicines (MDCO) Now Oversold
MarketNewsVideo.com - Tue Oct 07, 3:57PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
MDCO: 23.34 (+0.69)
The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 2014
Business Wire - Mon Oct 06, 1:22PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that data from its infectious disease portfolio will be presented at ID Week 2014, October 8-12 in Philadelphia, Pennsylvania.
MDCO: 23.34 (+0.69)
Actavis Expands Antibiotics Presence With Durata Buy
at Investor's Business Daily - Mon Oct 06, 9:58AM CDT
Specialty-drug giant Actavis (ACT) said Monday that it's acquiring biotech startup Durata Therapeutics for $675 million in cash, sending Durata's stock up more than 70% to a new high of 24.25 on the stock market today . Actavis' stock was flat in...
DRTX: 24.09 (+0.41), ACT: 232.13 (+5.46), CBST: 66.40 (-0.94), MDCO: 23.34 (+0.69), PFE: 28.28 (+0.35)
U.S. Market for Wound and Tissue Management 2014
M2 - Wed Oct 01, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xtlbb/u_s_market_for) has announced the addition of the "U.S. Market for Wound and Tissue Management 2014" report to their offering. The U.S market for wound and tissue management was driven by the introduction of newly FDA-approved products, and by demand due to the aging population, and increasing rates of both obesity and diabetes. The advanced wound dressings segment exhibited the highest growth in 2013. This growth will be due to the rising popularity of foam dressings, antimicrobial dressings and the influx of competitors and innovative products in the interactive dressing market. The reimbursement changes in 2014 will potentially have a negative impact on the growth of the interactive dressing market. Growth in the negative pressure wound therapy market was significantly affected by the competitive bidding process. This market is expected to rebound and post growth in the high single-digits over the forecast period. Growth will be supplemented by improved reimbursement rates for single use negative pressure wound therapy pumps and an increase in the number of competitors. Report Highlights: - Introduction of newly FDA-approved products - Reimbursement change effects on the market - Mainstay products in the wound closure market, such as sutures - Improved advanced wound closure devices, such as cyanoacrylate-based tissue adhesives - DME competitive bidding proccess effects on various markets Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Wound And Tissue Management Market Overview 4. Wound Closure Market 5. Static Compression Therapy Market 6. Dynamic Compression Therapy Market 7. Advanced Dressing Market Overview 8. Moist Dressing Market 9. Antimicrobial Dressing Market 10. Interactive Dressing Market 11. Non-Adherent Contact Layer Market 12. Traditional Wound Dressing Market 13. Hemostat Market 14. Tissue Sealant Market 15. Anti-Adhesion Market 16. Negative Pressure Wound Therapy Market Companies Mentioned - 3M - ArjoHuntleigh - BSN-JOBST - Baxter - Bayer - Bio Compression Systems - C. R. Bard - Carolon - Celox - Circulator Boot Corporation - ConvaTec - Covidien - Ethicon - Genzyme - HARTMANN-CONCO - HemCon - Integra Lifesciences - Lympha Press - MCS - Medicines Company - mediUSA - Medline - Organogenesis - Osiris - Pfizer - SIGVARIS - Smith & Nephew - Stryker (Orthovita) - Vascular Solutions - Z-Medica For more information visit http://www.researchandmarkets.com/research/9x...market_for
SNN: 31.36 (+0.51), MDCO: 23.34 (+0.69), VASC: 27.15 (+0.54)
The Medicines Company to Webcast Infectious Disease Care Investor & Analyst Day on September 24
Business Wire - Tue Sep 23, 6:00PM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a webcast and conference call of its upcoming Infectious Disease Care Investor & Analyst Day on Wednesday, September 24, 2014, from 9:00 am to 12:00 pm Eastern Time. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ.
MDCO: 23.34 (+0.69)
Frazier Healthcare Appoints David Socks as Venture Partner, Establishes Boston Presence
Business Wire - Fri Sep 19, 7:00AM CDT
Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announced today that David Socks has joined the Frazier Life Sciences team as a Venture Partner based in the Boston area to lead the firm's life sciences company creation efforts.
MKN: 10.27 (-0.01), MDCO: 23.34 (+0.69)
The Medicines Company to Review ORBACTIV(TM)(oritavancin) Launch Readiness on Tuesday, September 16, 2014
Business Wire - Fri Sep 12, 10:30AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a conference call for Tuesday, September 16 at 7:30 a.m. Eastern Time to discuss plans for launching ORBACTIV(TM) (oritavancin) for injection, the first and only single-dose, FDA-approved antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive pathogens.
MDCO: 23.34 (+0.69)
The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Business Wire - Wed Aug 27, 12:12PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014.
MDCO: 23.34 (+0.69)
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.
GILD: 106.67 (+4.46), MDCO: 23.34 (+0.69), AMGN: 144.09 (+6.58), RGDO: 1.15 (unch)
Sell These 5 Toxic Stocks Before It's Too Late
at The Street - Fri Aug 15, 6:56AM CDT
It's time to unload these toxic stocks from your portfolio.
GGB: 4.45 (-0.05), MDCO: 23.34 (+0.69), AGU: 85.51 (+1.67), RGP: 31.41 (+0.17), JNPR: 20.18 (+0.38)
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 16.35 (-0.39), QCOR: 93.60 (+1.52), MDCO: 23.34 (+0.69), PFE: 28.28 (+0.35), NKTR: 12.64 (-0.22)
Medicines Co Earnings In Retrospect: Down 1.7% in the Last 19 Days (MDCO)
Comtex SmarTrend(R) - Mon Aug 11, 12:09PM CDT
Two weeks ago on July 23rd, 2014 Medicines Co (NASDAQ:MDCO) reported earnings and analysts, on average, expected earnings of $0.39 on sales of $184.1 million. The company actually reported EPS of $0.31 on sales of $183.8 million, missing EPS estimates by $0.08 and matching revenue estimates. Shares of Medicines Co have slipped from $24.87 to $24.45, representing a loss of 1.7%, since the company reported earnings 19 days ago.
MDCO: 23.34 (+0.69)
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
DRTX: 24.09 (+0.41), BIIB: 326.77 (+15.36), VRTX: 108.16 (+3.39), RNA: 11.94 (+0.05), MDCO: 23.34 (+0.69), GILD: 106.67 (+4.46), RARE: 47.20 (+1.28), SHPG: 185.80 (+1.21), AMGN: 144.09 (+6.58), TKMR: 17.98 (-0.63), ABBV: 56.29 (+1.88), MNKD: 5.53 (+0.17), REGN: 381.01 (+14.88)
The Medicines Company's Orbactiv Approved on Solid SOLO Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 5:10PM CDT
Great news came in The Medicines Company's (MDCO) way when the FDA approved the company's antibiotic Orbactiv.
MDCO: 23.34 (+0.69), MYL: 52.04 (+1.73), HSP: 50.88 (+1.01)
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
ALNY: 88.92 (+0.93), MDCO: 23.34 (+0.69)
FDA Approves The Medicines Company's ORBACTIV(TM) (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
Business Wire - Wed Aug 06, 7:31PM CDT
--ORBACTIV(TM)U.S. Launch Expected in 2H/2014
MDCO: 23.34 (+0.69)
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
MDVN: 96.97 (+1.99), VRTX: 108.16 (+3.39), MDCO: 23.34 (+0.69), AUXL: 31.12 (+0.53), TKMR: 17.98 (-0.63), AMGN: 144.09 (+6.58), REGN: 381.01 (+14.88)
10.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Mon Aug 04, 10:07AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on July 17th, 2014 at $25.89. In approximately 3 weeks, Medicines Co has returned 10.27% as of today's recent price of $23.23.
MDCO: 23.34 (+0.69)
ORBACTIV(TM) (Oritavancin) Phase 3 SOLO II Trial Results Published in the Journal Clinical Infectious Diseases
Business Wire - Thu Oct 09, 3:53PM CDT
The Medicines Company (NASDAQ:MDCO) today announced the publication of the results from the SOLO II Phase 3 clinical trial of ORBACTIV (oritavancin) for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens.
MDCO: 23.34 (+0.69)
The Medicines Company to Announce Third Quarter 2014 Financial Results on Wednesday, October 22, 2014
Business Wire - Wed Oct 08, 6:20PM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, October 22 at 8:30 a.m. Eastern Time to discuss third quarter financial results, guidance and operational developments.
MDCO: 23.34 (+0.69)
RSI Alert: Medicines (MDCO) Now Oversold
MarketNewsVideo.com - Tue Oct 07, 3:57PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
MDCO: 23.34 (+0.69)
The Medicines Company Infectious Disease Portfolio Data to Be Presented at ID Week 2014
Business Wire - Mon Oct 06, 1:22PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that data from its infectious disease portfolio will be presented at ID Week 2014, October 8-12 in Philadelphia, Pennsylvania.
MDCO: 23.34 (+0.69)
Actavis Expands Antibiotics Presence With Durata Buy
at Investor's Business Daily - Mon Oct 06, 9:58AM CDT
Specialty-drug giant Actavis (ACT) said Monday that it's acquiring biotech startup Durata Therapeutics for $675 million in cash, sending Durata's stock up more than 70% to a new high of 24.25 on the stock market today . Actavis' stock was flat in...
DRTX: 24.09 (+0.41), ACT: 232.13 (+5.46), CBST: 66.40 (-0.94), MDCO: 23.34 (+0.69), PFE: 28.28 (+0.35)
U.S. Market for Wound and Tissue Management 2014
M2 - Wed Oct 01, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9xtlbb/u_s_market_for) has announced the addition of the "U.S. Market for Wound and Tissue Management 2014" report to their offering. The U.S market for wound and tissue management was driven by the introduction of newly FDA-approved products, and by demand due to the aging population, and increasing rates of both obesity and diabetes. The advanced wound dressings segment exhibited the highest growth in 2013. This growth will be due to the rising popularity of foam dressings, antimicrobial dressings and the influx of competitors and innovative products in the interactive dressing market. The reimbursement changes in 2014 will potentially have a negative impact on the growth of the interactive dressing market. Growth in the negative pressure wound therapy market was significantly affected by the competitive bidding process. This market is expected to rebound and post growth in the high single-digits over the forecast period. Growth will be supplemented by improved reimbursement rates for single use negative pressure wound therapy pumps and an increase in the number of competitors. Report Highlights: - Introduction of newly FDA-approved products - Reimbursement change effects on the market - Mainstay products in the wound closure market, such as sutures - Improved advanced wound closure devices, such as cyanoacrylate-based tissue adhesives - DME competitive bidding proccess effects on various markets Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Wound And Tissue Management Market Overview 4. Wound Closure Market 5. Static Compression Therapy Market 6. Dynamic Compression Therapy Market 7. Advanced Dressing Market Overview 8. Moist Dressing Market 9. Antimicrobial Dressing Market 10. Interactive Dressing Market 11. Non-Adherent Contact Layer Market 12. Traditional Wound Dressing Market 13. Hemostat Market 14. Tissue Sealant Market 15. Anti-Adhesion Market 16. Negative Pressure Wound Therapy Market Companies Mentioned - 3M - ArjoHuntleigh - BSN-JOBST - Baxter - Bayer - Bio Compression Systems - C. R. Bard - Carolon - Celox - Circulator Boot Corporation - ConvaTec - Covidien - Ethicon - Genzyme - HARTMANN-CONCO - HemCon - Integra Lifesciences - Lympha Press - MCS - Medicines Company - mediUSA - Medline - Organogenesis - Osiris - Pfizer - SIGVARIS - Smith & Nephew - Stryker (Orthovita) - Vascular Solutions - Z-Medica For more information visit http://www.researchandmarkets.com/research/9x...market_for
SNN: 31.36 (+0.51), MDCO: 23.34 (+0.69), VASC: 27.15 (+0.54)
The Medicines Company to Webcast Infectious Disease Care Investor & Analyst Day on September 24
Business Wire - Tue Sep 23, 6:00PM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a webcast and conference call of its upcoming Infectious Disease Care Investor & Analyst Day on Wednesday, September 24, 2014, from 9:00 am to 12:00 pm Eastern Time. The event will be held at the Company's Global Center 1 at 8 Sylvan Way in Parsippany, NJ.
MDCO: 23.34 (+0.69)
Frazier Healthcare Appoints David Socks as Venture Partner, Establishes Boston Presence
Business Wire - Fri Sep 19, 7:00AM CDT
Frazier Healthcare, a leading provider of venture and growth buyout capital to emerging healthcare companies, announced today that David Socks has joined the Frazier Life Sciences team as a Venture Partner based in the Boston area to lead the firm's life sciences company creation efforts.
MKN: 10.27 (-0.01), MDCO: 23.34 (+0.69)
The Medicines Company to Review ORBACTIV(TM)(oritavancin) Launch Readiness on Tuesday, September 16, 2014
Business Wire - Fri Sep 12, 10:30AM CDT
The Medicines Company (NASDAQ:MDCO) has scheduled a conference call for Tuesday, September 16 at 7:30 a.m. Eastern Time to discuss plans for launching ORBACTIV(TM) (oritavancin) for injection, the first and only single-dose, FDA-approved antibiotic for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive pathogens.
MDCO: 23.34 (+0.69)
The Medicines Company to Present New Data from its Infectious Disease Portfolio at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Business Wire - Wed Aug 27, 12:12PM CDT
The Medicines Company (NASDAQ:MDCO) today announced that a series of abstracts highlighting data from its Infectious Disease portfolio will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which takes place in Washington, DC from September 5-9, 2014.
MDCO: 23.34 (+0.69)
Regado Slumps on Permanent Termination of Revolixys Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:20PM CDT
Regado Biosciences (RGDO) announced that it is permanently terminating the enrollment process for its phase III study on Revolixys Kit.
GILD: 106.67 (+4.46), MDCO: 23.34 (+0.69), AMGN: 144.09 (+6.58), RGDO: 1.15 (unch)
Sell These 5 Toxic Stocks Before It's Too Late
at The Street - Fri Aug 15, 6:56AM CDT
It's time to unload these toxic stocks from your portfolio.
GGB: 4.45 (-0.05), MDCO: 23.34 (+0.69), AGU: 85.51 (+1.67), RGP: 31.41 (+0.17), JNPR: 20.18 (+0.38)
Pharma Equities Coverage -- Pfizer, BioDelivery Sciences Intl., The Medicines, Questcor Pharma, and Nektar Therapeutics
PR Newswire - Tue Aug 12, 8:00AM CDT
On Monday, August 11, 2014, the NASDAQ Composite ended at 4,401.33, up 0.70%, the Dow Jones Industrial Average advanced 0.10%, to finish the day at 16,569.98, and the S&P 500 closed at 1,936.92, up 0.28%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 700.04, up 0.01%, with the index also advancing 4.74 % in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), BioDelivery Sciences International Inc. (NASDAQ: BDSI), The Medicines Company (NASDAQ: MDCO), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at:
BDSI: 16.35 (-0.39), QCOR: 93.60 (+1.52), MDCO: 23.34 (+0.69), PFE: 28.28 (+0.35), NKTR: 12.64 (-0.22)
Medicines Co Earnings In Retrospect: Down 1.7% in the Last 19 Days (MDCO)
Comtex SmarTrend(R) - Mon Aug 11, 12:09PM CDT
Two weeks ago on July 23rd, 2014 Medicines Co (NASDAQ:MDCO) reported earnings and analysts, on average, expected earnings of $0.39 on sales of $184.1 million. The company actually reported EPS of $0.31 on sales of $183.8 million, missing EPS estimates by $0.08 and matching revenue estimates. Shares of Medicines Co have slipped from $24.87 to $24.45, representing a loss of 1.7%, since the company reported earnings 19 days ago.
MDCO: 23.34 (+0.69)
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
DRTX: 24.09 (+0.41), BIIB: 326.77 (+15.36), VRTX: 108.16 (+3.39), RNA: 11.94 (+0.05), MDCO: 23.34 (+0.69), GILD: 106.67 (+4.46), RARE: 47.20 (+1.28), SHPG: 185.80 (+1.21), AMGN: 144.09 (+6.58), TKMR: 17.98 (-0.63), ABBV: 56.29 (+1.88), MNKD: 5.53 (+0.17), REGN: 381.01 (+14.88)
The Medicines Company's Orbactiv Approved on Solid SOLO Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 5:10PM CDT
Great news came in The Medicines Company's (MDCO) way when the FDA approved the company's antibiotic Orbactiv.
MDCO: 23.34 (+0.69), MYL: 52.04 (+1.73), HSP: 50.88 (+1.01)
The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast "ALN-PCSsc for the Treatment of Hypercholesterolemia"
Business Wire - Thu Aug 07, 8:43AM CDT
The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the "ALN-PCSsc for the treatment of Hypercholesterolemia" RNAi Roundtable webcast on August 14, 2014. Event details are below.
ALNY: 88.92 (+0.93), MDCO: 23.34 (+0.69)
FDA Approves The Medicines Company's ORBACTIV(TM) (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
Business Wire - Wed Aug 06, 7:31PM CDT
--ORBACTIV(TM)U.S. Launch Expected in 2H/2014
MDCO: 23.34 (+0.69)
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
MDVN: 96.97 (+1.99), VRTX: 108.16 (+3.39), MDCO: 23.34 (+0.69), AUXL: 31.12 (+0.53), TKMR: 17.98 (-0.63), AMGN: 144.09 (+6.58), REGN: 381.01 (+14.88)
10.3% Return Seen to Date on SmarTrend Medicines Co Call (MDCO)
Comtex SmarTrend(R) - Mon Aug 04, 10:07AM CDT
SmarTrend identified a Downtrend for Medicines Co (NASDAQ:MDCO) on July 17th, 2014 at $25.89. In approximately 3 weeks, Medicines Co has returned 10.27% as of today's recent price of $23.23.
MDCO: 23.34 (+0.69)
